From: Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study
Methotrexate (n = 6) | Dupilumab (n = 11) | |||||
---|---|---|---|---|---|---|
At start | At follow-upa | p value | At start | At follow-upa | p value | |
Mean (range) | Mean (range) | Mean (range) | Mean (range) | |||
EASIb | 16.8 (7.4–30.3) | 2.8 (0–6.8) | 0.028* | 28.6 (6.2–50) | 5.2 (0.3–17.5) | 0.003* |
POEMc | 17.2 (6–27) | 6.7 (0–21) | 0.075 | 19.9 (11–28) | 4.9 (0–16) | 0.005* |
VASc | 5.7 (0.7–8.5) | 2.4 (0.1–7.8) | 0.028* | 6.3 (0.4–10) | 1.1 (0.1–3.4) | 0.007* |
DLQIb | 18.5 (10–26) | 8.7 (1–15) | 0.028* | 10.2 (1–25) | 1.6 (0–6) | 0.005* |
MADRSc | 14.6 (13–18) | 7.3 (3–12) | 0.034* | 13.7 (1–50) | 3.9 (0–10) | 0.028* |
Weightd (kg) | 74.8 (60–102) | 70.5 (57.7–85) | 0.075 | 87.1 (58–123) | 93.6 (65.5–136.4) | 0.003* |